Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Receivables (2020 - 2024)

Historic Receivables for Barinthus Biotherapeutics (BRNS) over the last 5 years, with Q4 2024 value amounting to $7.1 million.

  • Barinthus Biotherapeutics' Receivables rose 4545.64% to $7.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $7.1 million, marking a year-over-year increase of 4545.64%. This contributed to the annual value of $7.1 million for FY2024, which is 4545.64% up from last year.
  • As of Q4 2024, Barinthus Biotherapeutics' Receivables stood at $7.1 million, which was up 4545.64% from $5.2 million recorded in Q1 2024.
  • In the past 5 years, Barinthus Biotherapeutics' Receivables registered a high of $22.8 million during Q1 2022, and its lowest value of $2.7 million during Q1 2023.
  • In the last 5 years, Barinthus Biotherapeutics' Receivables had a median value of $5.3 million in 2021 and averaged $6.9 million.
  • Per our database at Business Quant, Barinthus Biotherapeutics' Receivables soared by 46929.8% in 2022 and then tumbled by 8827.07% in 2023.
  • Barinthus Biotherapeutics' Receivables (Quarter) stood at $3.2 million in 2020, then skyrocketed by 93.71% to $6.2 million in 2021, then surged by 61.07% to $10.1 million in 2022, then tumbled by 51.24% to $4.9 million in 2023, then skyrocketed by 45.46% to $7.1 million in 2024.
  • Its Receivables was $7.1 million in Q4 2024, compared to $5.2 million in Q1 2024 and $4.9 million in Q4 2023.